The Paris System for Reporting Urine Cytology - The WHY, HOW and WHAT to Watch Out For
Shikha Bose, MD
Urine cytology with cystoscopic examination remains the standard of practice in the initial evaluation of lower urinary tract lesions to rule out bladder cancer. However, cystoscopy is invasive and may miss some flat lesions, whereas cytology is not very useful in the detection of low-grade papillary neoplasms. Thus The Paris System for Reporting Urinary Cytology has been developed by members of the American Society of Cytopathology and the International Academy of Cytology to standardize the reporting of urine cytology cases with the the goal of improving the detection of high grade urothelial carcinoma. Morphologic criteria for the diagnosis of urothelial carcinoma and intermediate categories of atypia have been better defined. The criteria for each of the categories are based on the best available clinical outcomes evidence. The presentation will include a discussion of the morphologic features of the different diagnostic categories using case based examples and a discussion of the potential pitfalls.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- Understand the rationale for adopting The Paris System, a proposal for standardized reporting of urine cytology
- Evaluate the morphologic criteria for the various diagnostic categories and be able to assign diagnostic categories to cases
- Watch out for the potential pitfalls
Clinical Professor in Pathology
Cedar Sinai Medical Center
Los Angeles, California
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. Click here for a complete list.
The presenter has no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (MOC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Maintenance of Certification (MOC) process. Earn up to 2.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 MOC II
- 2.00 Participant